Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012.
URL: http://www.news-medical.net/news/20120929/Intarcia-announces-results-from-ITCA-650-phase-2-study-on-type-2-diabetes.aspx
No comments:
Post a Comment